Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5717562 | 0.82 | KDM4E (0.41) | ALDH1A1TSHRLMNAKMT2AKDM4E | |
| SCHEMBL8847207 | 0.79 | ALDH1A1 (0.48) | ALDH1A1ALOX15TSHRSMN1; SMN2MEN1 | |
| SCHEMBL20599552 | 0.78 | MAPT (0.47) | ALDH1A1ALOX15TSHRLMNAKMT2A | |
| SCHEMBL8847256 | 0.78 | ALDH1A1 (0.46) | ALDH1A1ALOX15TSHRSMN1; SMN2MEN1 | |
| SCHEMBL8536765 | 0.76 | ALDH1A1 (0.44) | ALDH1A1ALOX15TSHRSMN1; SMN2MEN1 | |
| SCHEMBL7504616 | 0.76 | ALDH1A1 (0.40) | ALDH1A1ALOX15TSHRSMN1; SMN2LMNA | |
| SCHEMBL7504625 | 0.76 | ALDH1A1 (0.40) | ALDH1A1ALOX15TSHRSMN1; SMN2LMNA | |
| SCHEMBL9632759 | 0.74 | ALDH1A1 (0.43) | ALDH1A1ALOX15TSHRSMN1; SMN2LMNA | |
| SCHEMBL3478477 | 0.74 | TSHR (0.56) | ALDH1A1TSHRSMN1; SMN2LMNAKDM4E | |
| SCHEMBL11013545 | 0.73 | NR4A1 (0.50) | ALDH1A1ALOX15TSHRSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016079502-A1 | METAL CHELATING COMPOUNDS FOR USE IN TREATING DISEASES | UNIVERSITY OF NORTHUMBRIA (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079502-A1 | METAL CHELATING COMPOUNDS FOR USE IN TREATING DISEASES | UNIVERSITY OF NORTHUMBRIA (GB) | 2016-05-26 | — | — | WO | disclosed |
| EP-2396301-A2 | SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010091876-A2 | SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2010-08-19 | — | — | WO | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | ALDH1A1 2549/4885ALOX15 2590/4885TSHR 723/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | ALDH1A1 2549/4885ALOX15 2590/4885TSHR 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.